Arthur has extensive experience across a wide range of functional areas and segments of the life sciences industry. He has been CEO of two early-stage life sciences companies in the medical device and drug discovery areas. His recent engagements have included roles as interim CEO of Amasa Therapeutics, an oncology company developing engineered cell therapies to treat glioblastoma and solid tumors, and CBO of Nuritas, Ltd., an artificial intelligence based, peptide-focused drug discovery company.

Additional leadership and advisory roles have included Antyllus Therapeutics, Smith Therapeutics, and Gro Biosciences, companies developing cardiovascular therapeutics, cell-based therapeutics for neurodegenerative disease, and novel therapeutics based on computational protein design and synthetic biology, respectively. Through his consulting company, Hiller Life Sciences Strategies, LLC, he also provides commercial strategy consulting, including recent engagements with venture-backed companies focused on obesity, the microbiome and melanoma, and major multinational pharma companies launching new products in women’s health and rare diseases, an early stage diagnostic company, and a medical device company with novel technology for otolaryngology applications.

Arthur has also held executive positions in general management, marketing, sales, sales management, and business development at Millennium Pharmaceuticals, Inc., Merck and Co, and two other large, multinational pharmaceutical companies. At Millennium, he was Senior Vice President, responsible for the cardiovascular business unit, including sales and marketing of INTEGRILIN®, new product marketing for the Millennium pipeline, and customer segment and channel management.

He joined Millennium in 2001 as General Manager, Inflammation, and was subsequently named General Manager, Cardiovascular in 2002, and Senior Vice President, Global Strategic Marketing in 2003. Arthur holds a Bachelor’s Degree in journalism from Northwestern University and a Master’s Degree in Business Policy from Columbia University. He serves as Lecturer and faculty member of the Healthcare Ventures class at MIT, as well as a mentor for the MIT IMPACT Innovation and IDEA² programs and the Nucleate Program, and in Advisory Board, fundraising, and business development capacities for a wide range of start-up and early stage companies in the Boston area.